Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

UnknownOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

December 31, 2022

Conditions
ObservationalProspective
Interventions
DRUG

Trastuzumab+TP

Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).

Trial Locations (1)

050011

RECRUITING

Fourth Hospital of Hebei Medical University, China, Shijiazhuang

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OrigiMed

INDUSTRY

lead

Hebei Medical University Fourth Hospital

OTHER

NCT03728829 - Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer | Biotech Hunter | Biotech Hunter